N/A Completed N=21 Randomized Double-blind Basic Science

Hypoglycemia and the Mineralocorticoid Receptor

Hypoglycemia

Source: ClinicalTrials.gov NCT01394627 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Nov 2017

Primary outcomePrimary: Change From Baseline in Cardiovascular Autonomic Function — -16.00; -16.59 ms/mmHg

Summary

The purpose of this study is to look at whether blockade of the mineralocorticoid receptor will result in changes in the cardiovascular and inflammatory response to hypoglycemia.

Outcome Measures

Outcome	Result	p-value
PRIMARY Change From Baseline in Cardiovascular Autonomic Function	-16.00; -16.59	—
SECONDARY Change From Baseline in Inflammation	2.03; 2.61	—

Eligibility Criteria

Inclusion Criteria

Healthy volunteers
Males and females age 18 to 40 years

Exclusion Criteria

Pregnancy
Lactation
Menopause
Any medical condition other than treated hypothyroidism.
Alcoholism
Active tobacco use
In all subjects, any individuals on oral, injected, inhaled or topical corticosteroids within the last year or oral contraceptives within the past 3 months will be excluded.
Use of medications other than physiological thyroxine replacement
Serum potassium >5.0 mmol/L
Estimated glomerular filtration rate < 60 mL/min

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01394627). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.